Therefore, in this study we aimed for the blocking of TSP-1 mediated TGF-β activation and for the reduction of renal inflammation in the well-established Fischer-Lewis rat model of CAN 28 weeks after the start of the long-term TSP-2 gene therapy. The gene discussed is TGFB1; the disease is Crouzon syndrome-acanthosis nigricans syndrome.